Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Specific Plasma Autoantibody Reactivity in Myelodysplastic Syndromes

    ... Increased autoantibody reactivity in plasma from Myelodysplastic Syndromes (MDS) patients may provide ... study we investigated Immunoglobulin G reactivity in plasma from MDS, Acute Myeloid Leukemia post MDS patients, and a healthy ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Decreased plasma cytokines associate with low platelet counts in aplastic anemia and immune thrombocytopenic purpura

    ... Background: We previously found plasma levels of CD40 ligand (CD40L), chemokine (C-X-C motif) ligand 5 ... platelets. Patients/Methods: We measured cytokines in the plasma of immune thrombocytopenic purpura (ITP) and AA patients using the ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes

    ... systems. The goal of this study is to identify plasma microRNAs useful for classification and risk stratification of ... technology (NanoString) to profile microRNA expression in plasma samples of 72 patients with myelodysplastic syndromes and 12 healthy ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

    ... dynamic change over time after treatment. We examined plasma concentrations of hematopoietic growth factors sequentially in 55 ... noted between TPO levels and platelet counts. The increased plasma TPO levels could be required to maintain normal platelet counts in ...

    Research Article last updated 10/23/2017 - 11:19am.

  5. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

    ... dynamic change over time post treatment. We examined plasma concentrations of hematopoietic growth factors sequentially in 55 ... noted between TPO levels and platelet counts. The increased plasma TPO levels could be required to maintain normal platelet counts in ...

    Research Article last updated 10/02/2017 - 9:40am.

  6. A plasma microRNA signature as a biomarker for acquired aplastic anemia

    ... monitor the disease. We analyzed circulating miRNAs in plasma samples of aplastic anemia patients in order to identify ... miRNAs. A total of 179 miRNAs were analyzed in 35 plasma samples from 13 aplastic anemia, 11 myelodysplastic syndrome, and 11 healthy controls using the Serum/Plasma Focus microRNA PCR Panel. Subsequently, 19 miRNAs from the discovery set ...

    Research Article last updated 10/06/2016 - 9:39am.

  7. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

    ... eculizumab was associated with significant decreases in plasma markers of coagulation activation (F1+2, P=0.012, and D-dimers, ... P=0.0002). Eculizumab treatment also significantly reduced plasma markers of endothelial cell activation (t-PA, P=0.0005, sVCAM-1, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

    ... Rabbit antithymocyte globulin was detectable in plasma for longer periods than horse antithymocyte globulin; rabbit antithymocyte globulin in plasma retained functional capacity to bind to lymphocytes for up to one ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Complement Blockade with a C1 Esterase Inhibitor in Paroxysmal Nocturnal Hemoglobinuria

    ... C1 esterase inhibitor (C1INH) is an endogenous human plasma protein that has broad inhibitory activity in the complement ... pathway. In this study, we show that commercially available plasma derived C1INH prevents lysis induced by the alternative complement ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... in a phase 1 dose-finding study. AZA has a short plasma half-life and DNA incorporation is S-phase-restricted; extending ...

    Research Article last updated 07/20/2018 - 5:15pm.